Affiliation:
1. Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne NE1 3BZ, UK
2. Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
Abstract
The splicing regulator proteins SRSF1 (also known as ASF/SF2) and SRSF3 (also known as SRP20) belong to the SR family of proteins and can be upregulated in cancer. TheSRSF1gene itself is amplified in some cancer cells, and cancer-associated changes in the expression ofMYCalso increaseSRSF1gene expression. Increased concentrations of SRSF1 protein promote prooncogenic splicing patterns of a number of key regulators of cell growth. Here, we review the evidence that upregulation of the SR-related Tra2βprotein might have a similar role in cancer cells. TheTRA2Bgene encoding Tra2βis amplified in particular tumours including those of the lung, ovary, cervix, stomach, head, and neck. BothTRA2BRNA and Tra2βprotein levels are upregulated in breast, cervical, ovarian, and colon cancer, and Tra2βexpression is associated with cancer cell survival. TheTRA2Bgene is a transcriptional target of the protooncogene ETS-1 which might cause higher levels of expression in some cancer cells which express this transcription factor. Known Tra2βsplicing targets have important roles in cancer cells, where they affect metastasis, proliferation, and cell survival. Tra2βprotein is also known to interact directly with the RBMY protein which is implicated in liver cancer.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献